Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Preliminary results from Samaritan Pharmaceuticals' phase II trial of the company's oral HIV entry inhibitor SP-01A have shown that the drug induced antiviral activity in patients experiencing HIV drug resistance in only 10 days.
Subscribe to our email newsletter
The study, a phase II double-blind, placebo controlled, multi-dose study in treatment-experience HIV patients, assessed SP01A’s safety and effect on viral load in HIV-1 positive individuals, with evidence of increasing viral load, despite treatment with antiretroviral therapy.
In the preliminary finding, SP-01A was found to have a 0.4 log10 difference between the high dose group, which received SP-01A 800mg/day and the placebo control group.
In addition, there was a dose dependent relationship in the number of subjects who had a reduction in viral load with the 800mg/day dose group showing the most difference as compared to placebo (55% vs. 0%, respectively).
“Clinically SP-01A has always been tested in concert with other antiretroviral drugs, this is the first time it was tested alone. We are very encouraged with the results and look forward to developing SP-01A to hopefully be the first orally administered entry cell inhibitor drug with a ‘firewall’ mechanism of action,” stated Dr Greeson, CEO of Samaritan Pharmaceuticals.